Gedea Biotech's pHyph included in Swedish clinical guideline for bacterial vaginosis

Gedea Biotech announced that its vaginal tablet, pHyph®, has been included in a major Swedish national clinical guideline for the treatment of bacterial vaginosis (BV). This inclusion marks a significant step in establishing pHyph as a clinically recognised treatment option.

The updated guidance, issued by the Swedish Society of Obstetrics and Gynecology (SFOG), specifically mentions pHyph as an antibiotic-free, CE-marked vaginal treatment. It further details the product's microbiome-modulating mechanism of action and references its clinical evidence.

Bacterial vaginosis is a common condition that can lead to discomfort and increased susceptibility to other infections. The growing concern over antibiotic resistance has spurred interest in alternative treatment modalities.

Gedea Biotech focuses on developing and commercializing non-antibiotic treatments aimed at restoring vaginal health. pHyph represents the company's initial offering in this therapeutic area.